Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F22%3A00128080" target="_blank" >RIV/00216224:14160/22:00128080 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial
Original language description
Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across all disease domains. Izokibep, a first-in-class fusion protein, is a unique IL-17A inhibitor with very high potency (Kd =0.3 pM), small molecular size (18.6 kD versus mAbs ~ 150 kD), and attachment to albumin. Treat to target is an important strategy to optimize disease control (reducing inflammation, limiting damage) as well as optimizing quality of life in PsA. Many composite measures of disease control have been proposed for clinical decision-making, including ACR scores, DAS28-CRP, DAPSA scores, and MDA. Here, we report the efficacy results of izokibep 40 mg Q2W and 80 mg Q2W versus placebo across a range of disease outcome measures as well as relevant safety data over 16 weeks compared to placebo.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)